Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Diagnosis of operable stage IB, II, or IIIA non-small cell lung cancer
• •* Tumor diameter of at least 3 cm
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 to 75
• •Performance status:
• •ECOG 0-2
• •Life expectancy:
• •At least 3 months
• •Hematopoietic:
• •WBC at least 3,000/mm\^3
• •Platelet count at least 100,000/mm\^3
• •Hepatic:
• •Bilirubin no greater than 2.0 mg/dL
• •AST less than 2 times upper limit of normal (ULN)
• •Lactate dehydrogenase less than 2 times ULN
• •Hepatitis B and C negative
• •Renal:
• •Creatinine no greater than 1.4 mg/dL
• •Other:
• •Positive cell mediated immunity test (i.e., greater than 5 mm induration in 48 hours with purified protein derivative (of tuberculin), candida, and mumps intradermal injection skin test)
• •HIV negative
• •No active systemic infection
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •At least 4 weeks since prior biological materials
• •Chemotherapy:
• •At least 4 weeks since prior cytotoxic or chemotherapeutic agents
• •Concurrent chemotherapy allowed after surgery and before vaccination
• •Endocrine therapy:
• •No concurrent steroid therapy
• •Radiotherapy:
• •At least 4 weeks since prior radiotherapy
• •Concurrent radiotherapy allowed after surgery and before vaccination
• •Surgery:
• •See Disease Characteristics